Effects of the Dual Sodium-Glucose Linked Transporter Inhibitor, Licogliflozin Versus Placebo or Empagliflozin in Patients With Type 2 Diabetes and Heart Failure
British Journal of Clinical Pharmacology - United Kingdom
doi 10.1111/bcp.14248
Full Text
Open PDFAbstract
Available in full text
Categories
Date
March 10, 2020
Authors
Publisher
Wiley